Charles River Laboratories Return on Tangible Equity 2010-2024 | CRL
Current and historical return on tangible equity values for Charles River Laboratories (CRL) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
| Charles River Laboratories Return On Tangible Equity Historical Data |
| Date |
TTM Net Income |
Tangible Equity |
Return on Tangible Equity |
| 2024-09-30 |
$0.42B |
$-0.12B |
-192.71% |
| 2024-06-30 |
$0.44B |
$-0.15B |
-144.35% |
| 2024-03-31 |
$0.44B |
$-0.25B |
-107.12% |
| 2023-12-31 |
$0.47B |
$-0.36B |
-88.10% |
| 2023-09-30 |
$0.47B |
$-0.46B |
-72.39% |
| 2023-06-30 |
$0.48B |
$-0.59B |
-81.86% |
| 2023-03-31 |
$0.50B |
$-0.75B |
-96.82% |
| 2022-12-31 |
$0.49B |
$-0.82B |
-133.70% |
| 2022-09-30 |
$0.44B |
$-0.20B |
-93.71% |
| 2022-06-30 |
$0.44B |
$-0.27B |
-86.35% |
| 2022-03-31 |
$0.42B |
$-0.15B |
-80.88% |
| 2021-12-31 |
$0.39B |
$-1.23B |
-90.88% |
| 2021-09-30 |
$0.40B |
$-0.39B |
-649.18% |
| 2021-06-30 |
$0.40B |
$-0.31B |
788.06% |
| 2021-03-31 |
$0.38B |
$0.21B |
328.23% |
| 2020-12-31 |
$0.36B |
$0.24B |
1693.02% |
| 2020-09-30 |
$0.30B |
$0.05B |
-885.29% |
| 2020-06-30 |
$0.27B |
$-0.05B |
-425.10% |
| 2020-03-31 |
$0.25B |
$-0.16B |
-274.79% |
| 2019-12-31 |
$0.25B |
$0.02B |
-854.24% |
| 2019-09-30 |
$0.23B |
$-0.07B |
-667.63% |
| 2019-06-30 |
$0.22B |
$-0.16B |
-572.55% |
| 2019-03-31 |
$0.23B |
$0.09B |
-576.10% |
| 2018-12-31 |
$0.23B |
$0.00B |
-22700.00% |
| 2018-09-30 |
$0.14B |
$-0.08B |
320.47% |
| 2018-06-30 |
$0.13B |
$-0.17B |
127.72% |
| 2018-03-31 |
$0.13B |
$0.24B |
74.89% |
| 2017-12-31 |
$0.12B |
$0.18B |
98.20% |
| 2017-09-30 |
$0.20B |
$0.15B |
261.39% |
| 2017-06-30 |
$0.18B |
$0.12B |
404.40% |
| 2017-03-31 |
$0.17B |
$0.05B |
1081.97% |
| 2016-12-31 |
$0.16B |
$-0.02B |
209.46% |
| 2016-09-30 |
$0.14B |
$0.03B |
103.27% |
| 2016-06-30 |
$0.14B |
$-0.00B |
106.21% |
| 2016-03-31 |
$0.16B |
$0.29B |
82.89% |
| 2015-12-31 |
$0.15B |
$0.23B |
93.02% |
| 2015-09-30 |
$0.15B |
$0.01B |
77.23% |
| 2015-06-30 |
$0.14B |
$0.22B |
58.64% |
| 2015-03-31 |
$0.13B |
$0.19B |
53.85% |
| 2014-12-31 |
$0.13B |
$0.34B |
44.21% |
| 2014-09-30 |
$0.12B |
$0.22B |
41.70% |
| 2014-06-30 |
$0.12B |
$0.20B |
37.20% |
| 2014-03-31 |
$0.11B |
$0.39B |
31.28% |
| 2013-12-31 |
$0.10B |
$0.33B |
31.35% |
| 2013-09-30 |
$0.10B |
$0.34B |
31.51% |
| 2013-06-30 |
$0.09B |
$0.33B |
29.64% |
| 2013-03-31 |
$0.10B |
$0.31B |
31.84% |
| 2012-12-31 |
$0.10B |
$0.31B |
33.05% |
| 2012-09-30 |
$0.11B |
$0.30B |
38.60% |
| 2012-06-30 |
$0.10B |
$0.28B |
39.96% |
| 2012-03-31 |
$0.10B |
$0.27B |
41.11% |
| 2011-12-31 |
$0.11B |
$0.24B |
44.04% |
| 2011-09-30 |
$-0.26B |
$0.24B |
-93.32% |
| 2011-06-30 |
$-0.31B |
$0.28B |
-95.63% |
| 2011-03-31 |
$-0.32B |
$0.24B |
-73.89% |
| 2010-12-31 |
$-0.34B |
$0.37B |
-60.41% |
| 2010-09-30 |
$0.02B |
$0.39B |
3.72% |
| 2010-06-30 |
$0.09B |
$0.75B |
12.02% |
| 2010-03-31 |
$0.11B |
$0.73B |
15.34% |
| 2009-12-31 |
$0.11B |
$0.71B |
17.06% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical Services |
$9.516B |
$4.129B |
|
Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research and drug development efforts. The company has a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP. This helps support its clients from target identification through non-clinical development. Charles River also provides a line of products and services to support clients' manufacturing activities. Utilizing the company's broad portfolio of products and services, clients can create a more flexible drug development model, aiming cost reduction, productivity enhancement and increase in speed to market. Charles River currently has three reporting segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA) and Manufacturing Support.
|
